Shots:
- Monopar has highlighted P-III (FoCus) trial data assessing ALXN1840 (tiomolibdate choline, TMC; n=77) vs SoC (n=35) in Wilson disease pts with neurologic symptoms at baseline, at AAN’26
- Trial showed better outcomes with ALXN1840, with lower neurologic worsening (9% vs 25%) & higher improvement (45% vs 32%) vs SoC, plus greater CGI-S (61% vs 17%) & CGI-I (47% vs 19%) improvements at Wk. 48
- ALXN1840 showed durable neurologic benefit sustained over ~3 years, with consistent efficacy in both treatment-naïve & experienced pts, supporting its potential & planned NDA submission to the US FDA in mid-2026
Ref: Monopar | Image: Monopar |Press Release
Related News: Novo Nordisk Reports Positive P-III (HIBISCUS) Study Data for Etavopivat in Sickle Cell Disease
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
